Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Endothelin antagonism with bosentan: current status and future perspectives Ono K; Matsumori ACardiovasc Drug Rev 2002[Win]; 20 (1): 1-18Endothelin receptor antagonists have been proposed for the treatment of a variety of disorders in which the endothelins may act as pathogenic mediators, such as hypertension, congestive heart failure, and cerebral vasospasm. Bosentan is a nonpeptide competitive antagonist, which can be a good tool for studying the endothelin system. It is specific for the endothelin system and blocks the actions of endothelin at both mammalian receptors (A and B). Bosentan has recently moved into Phase III clinical trial. This review will attempt to overview the experimental and clinical effects of bosentan.|*Endothelin Receptor Antagonists[MESH]|Animals[MESH]|Antihypertensive Agents/adverse effects/chemistry/pharmacokinetics/*pharmacology/*therapeutic use[MESH]|Bosentan[MESH]|Cardiovascular Diseases/*drug therapy/physiopathology[MESH]|Endothelins/*antagonists & inhibitors/physiology[MESH]|Humans[MESH]|Sulfonamides/adverse effects/chemistry/pharmacokinetics/*pharmacology/*therapeutic use[MESH] |
